Parasitology Research

, 105:155 | Cite as

Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis

  • Marta Mateo
  • Laurence Maynard
  • Claudia Vischer
  • Paolo Bianciardi
  • Guadalupe MiróEmail author
Original Paper


The aim of this study was to compare the efficacy and safety of oral administration of miltefosine (Milteforan®) at 2 mg/kg/day for 28 days (Group M; n = 60) with a subcutaneous administration of meglumine antimoniate (Glucantime®) at 50 mg/kg/12 h or at 100 mg/kg/day for 28 days (Group G; n = 59) in the treatment of canine leishmaniosis in dogs. Out of 119 dogs included in the study, 90 could be used for efficacy assessment and 112 for safety assessment. Treated dogs were followed up for 6 weeks, with re-checks every 14 days. The mean total clinical scores significantly decreased throughout the study in both treatment groups. The evolution of parasitological results after treatment (D42) shows a high percentage of dogs with negative bone marrow smears, 90% and 91.3% in groups M and G respectively, and did not significantly differ between groups (p = 0.8066). Out of the 112 dogs used for the safety assessment, only 26 dogs (23.2%) presented product-related adverse events concerning the gastrointestinal tract. These results showed that miltefosine at 2 mg/kg once daily can be safely used over a 28-day period in the treatment of canine leishmaniosis and provides both a steadily increasing improvement of the clinical signs and a good leishmanicidal efficacy.


Allopurinol Miltefosine Bone Marrow Smear Pyriproxyfen Pyrantel 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This study was supported by VIRBAC S.A. (France). The authors are indebted to all practitioners involved for their valuable help.


  1. Alvar J, Cañavate C, Molina M, Moreno J, Nieto J (2004) Canine leishmaniasis. Adv Parasitol 57:1–88CrossRefPubMedGoogle Scholar
  2. Baneth G (2006) Leishmaniases. In: Green CE (ed) Infectious disease of the dog and cat. Elsevier, St Louis, Missouri, pp 685–696Google Scholar
  3. Baneth G, Shaw SE (2002) Chemotherapy of canine leishmaniosis. Vet Parasitol 106:315–324CrossRefPubMedGoogle Scholar
  4. Bhattacharya SK, Jha TK, Sundar S, Thakur CP, Engel J, Sindermann H, Junge K, Karbwang J, Bryceson AD, Berman JD (2004) Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin Infect Dis 38(2):217–221CrossRefPubMedGoogle Scholar
  5. Bourdoiseau G, Denerolle P (2000) Traitement de la leishmaniose canine: actualités. Revue Méd Vét 151:395–400Google Scholar
  6. Croft SL, Seifert K, Duchêne M (2003) Antiprotozoal activities of phospholipids analogues. Mol Biochem Parasitol 126:165–172CrossRefPubMedGoogle Scholar
  7. Cruz I, Cañavate C, Rubio JM, Morales MA, Chicharro C, Laguna F, Jiménez-Mejías M, Sirena G, Videla S, Alvar J (2002) A nested polymerase chain reaction (Ln-PCR) for diagnosing and monitoring Leishmania infantum infection in patients co-infected with human immunodeficiency virus. Trans R Soc Trop Med Hyg 96(1):185–189CrossRefGoogle Scholar
  8. Denerolle P (1996) Leishmaniose canine: difficultés du diagnostic et du traitement (125 cas). Prat Méd Chir Anim Comp 31:137–145Google Scholar
  9. Denerolle P, Bourdoiseau G (1999) Combination allopurinol and antimony treatment versus antimony alone and allopurinol alone in the treatment of canine leishmaniasis (96 cases). J Vet Intern Med 13:413–415CrossRefPubMedGoogle Scholar
  10. Gomes YM, Paiva Cavalcanti M, Lira RA, Abath FG, Alves LC (2008) Diagnosis of canine visceral leishmaniasis: biotechnological advances. Vet J 175(1):45–52CrossRefPubMedGoogle Scholar
  11. Gramiccia M, Gradoni L, Orsini S (1992) Decreased sensitivity to meglumine antimoniate (Glucantime®) of Leishmania infantum isolated from dogs after several courses of drug treatment. Ann Trop Med Parasitol 86:613–620PubMedGoogle Scholar
  12. Ikeda-García FA, Lopes RS, Marques FJ, Lima VMF, Morinishi CK, Bonello FL, Zanette MF, Perri SHV, Feitosa MM (2007) Clinical and parasitological evaluation of dogs naturally infected by Leishmania (Leishmania) chagasi submitted to treatment with meglumine antimoniate. Vet Parasitol 143:254–259CrossRefPubMedGoogle Scholar
  13. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, Voss A, Berman J (1999) Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 341(24):1795–1800CrossRefPubMedGoogle Scholar
  14. Koutinas AF, Saridomichelakis MN, Mylonakis ME, Leontides L, Polizopoulou Z, Billinis C, Argyriadis D, Diakou N, Papadopoulos O (2001) A randomised, blinded, placebo-controlled clinical trial with allopurinol in canine leishmaniosis. Vet Parasitol 98(4):247–261CrossRefPubMedGoogle Scholar
  15. Liste F, Gascon M (1995) Allopurinol in the treatment of canine visceral leishmaniasis. Vet Rec 137:23–24PubMedGoogle Scholar
  16. Manna L, Viola E, Pavone LM, Staiano N, Gravino AE (2005) Leishmanicidal activity of miltefosine in acute renal failure of naturally infected dogs. Worldleish3, Palermo-Terrasini, Sicily, Italy, p 165Google Scholar
  17. Manna L, Reale S, Vitale F, Picillo E, Pavone LM, Gravino AE (2008a) Real-time PCR assay in Leishmania-infected dogs treated with meglumine antimoniate and allopurinol. The Veterinary Journal 177:279–282CrossRefPubMedGoogle Scholar
  18. Manna L, Vitale F, Reale S, Picillo E, Neglia G, Vescio F, Gravino AE (2008b) Study of efficacy of miltefosine and allopurinol in dogs with leishmaniosis. The Veterinary Journal, doi: 10.1016/j.tvjl.2008.08.009.
  19. Miró G, Mateo M, Cruz I, Cañavate C, Nieto J, Montoya A, Galy S, Médaille C, Alvar J (2005) Miltefosine: a new treatment for canine leishmaniosis. Preliminary results. Worldleish3, Palermo-Terrasini, Sicily, Italy, p 175Google Scholar
  20. Miró G, Cardoso L, Pennisi MG, Oliva G, Baneth G (2008a) Canine leishmaniosis—new concepts and insights on an expanding zoonosis: part two. Trends in Parasitology 738:331–337Google Scholar
  21. Miró G, Oliva G, Cruz I, Cañavate C, Mortarino M, Vischer C, Bianciardi P (2008b) Multi-centric and controlled clinical field study to evaluate the efficacy and safety of the combination of miltefosine and allopurinol in the treatment of canine leishmaniosis. Veterinary Dermatology 19(Suppl. 1):7–8Google Scholar
  22. Moreira MA, Luvizotto MC, García JF, Corbett CE, Laurenti MD (2007) Comparison of parasitological, immunological and molecular methods for the diagnosis of leishmaniosis in dogs with different clinical signs. Vet Parasitol 145:245–252CrossRefPubMedGoogle Scholar
  23. Noli C, Auxilia ST (2005) Treatment of canine Old World visceral leishmaniasis: a systematic review. Veterinary Dermatology 16(4):213–232CrossRefPubMedGoogle Scholar
  24. Oliva G, Scalone A, Foglia Manzillo V, Gramiccia M, Pagano A, Di Muccio T, Gradoni L (2006) Incidence and time course of Leishmania infantum infections examined by parasitological, serologic, and Nested-PCR techniques in a cohort of naïve dogs exposed to three consecutive transmission seasons. J Clin Microbiol 44(4):1318–1322CrossRefPubMedGoogle Scholar
  25. Pasa S, Ozensoy Toz S, Voyvoda H, Ozbel Y (2005) Clinical and serological follow-up in dogs with visceral leishmaniosis treated with allopurinol and sodium stibogluconate. Vet Parasitol 128:243–249CrossRefPubMedGoogle Scholar
  26. Pennisi MG, De Majo M, Masucci M, Britti D, Vitale F, Del Maso R (2005) Efficacy of the treatment of dogs with leishmaniosis with a combination of metronidazole and spiramycin. Vet Rec 156(11):346–349PubMedGoogle Scholar
  27. Pouyol O (2004) Leishmaniose: des consensus diagnostiques et thérapeutiques. La Dépêche Vétérinaire, no 830Google Scholar
  28. Riera C, Valladares JE, Gallego M, Aisa MJ, Castillejo S, Fisa R, Ribas N, Carrio J, Alberola J, Arboix M (1999) Serological and parasitological follow-up in dogs experimentally infected with Leishmania infantum and treated with meglumine antimoniate. Vet Parasitol 84(1–2):33–47CrossRefPubMedGoogle Scholar
  29. Sainz A, Delgado S, Amusategui I, Tesouro MA, Carmenes P (1996) Seroprevalence of canine ehrlichiosis in Castilla-León (North-West Spain). Prev Vet Med 29:1–7CrossRefGoogle Scholar
  30. Saridomichelakis MN, Mylonakis ME, Leontides LS, Ch Billinis, Koutinas AF, Galatos AD, Gouletsou P, Diakou A, Kontos VI (2005) Periodic administration of allopurinol is not effective for the prevention of canine leishmaniosis (Leishmania infantum) in the endemic areas. Vet Parasitol 130:199–205CrossRefPubMedGoogle Scholar
  31. Solano-Gallego L, Riera C, Roura X, Iniesta L, Gallego M, Valladares JE, Fisa R, Castillejo S, Alberola J, Ferrer L, Arboix M, Portus M (2001a) Leishmania infantum-specific IgG, IgG1 and IgG2 antibody responses in healthy and ill dogs from endemic areas. Evolution in the course of infection and after treatment. Vet Parasitol 96(4):265–276CrossRefPubMedGoogle Scholar
  32. Solano-Gallego L, Morell P, Arboix M, Alberola J, Ferrer L (2001b) Prevalence of Leishmania infantum infections in dogs living in an area of canine leishmaniasis endemicity using PCR on several tissues and serology. J Clin Microbiol 39:560–563CrossRefPubMedGoogle Scholar
  33. Sindermann H, Engel J (2006) Development of miltefosine as on oral treatment for leismaniasis. Trans R Soc Trop Med Hyg 100:S17–S20CrossRefPubMedGoogle Scholar
  34. Sundar S, Rosenkaimer F, Makharia MK, Goyal AK, Mandal AK, Voss A, Hilgard P, Murray HW (1998) Trial of oral miltefosine for visceral leishmaniasis. Lancet 352:1821–1823CrossRefPubMedGoogle Scholar
  35. Sundar S, Makharia A, More DK, Agrawal G, Voss A, Fischer C, Bachmann P, Murray HW (2000) Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin Infect Dis 31(4):1110–1113CrossRefPubMedGoogle Scholar
  36. Sundar S, Jha TK, Thakur CP, Bhattacharya SK, Rai M (2006) Oral miltefosine for the treatment of Indian visceral leishmaniasis. Trans R Soc Med Hyg 100:S26–33CrossRefGoogle Scholar
  37. Valladares JE, Riera C, Gonzalez-Ensenyat P, Diez-Cascon A, Ramos G, Solano-Gallego L, Gallego M, Portus M, Arboix M, Alberola J (2001) Long term improvement in the treatment of canine leishmaniosis using an antimony liposomal formulation. Vet Parasitol 97(1):15–21CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Marta Mateo
    • 1
  • Laurence Maynard
    • 2
  • Claudia Vischer
    • 2
  • Paolo Bianciardi
    • 3
  • Guadalupe Miró
    • 1
    Email author
  1. 1.Dpto. Sanidad Animal, Facultad de VeterinariaUniversidad Complutense de MadridMadridSpain
  2. 2.Virbac SACarros CedexFrance
  3. 3.Via dell’Usignolo1 MilanoItaly

Personalised recommendations